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Background: The authors report on the conception and first clinical application of a donut-shaped high-dose configuration for 
proton therapy (PT). This approach allows one to intensify target volume dose coverage for targets encompassing a critical, 
dose-limiting structure – like here, the cauda equina –, whilst delivering minimal dose to other healthy structures surrounding 
the target, thereby reducing the integral dose.
Methods and Results: Intensity-modulated PT methods (IMPT) for spot scanning were applied to create and deliver a donut-
shaped high-dose configuration with protons, allowing treating > 75% of the target with at least 95% of the prescribed dose of 
72.8 CGE, whilst restricting dose to the cauda equina to 60–65 CGE. Integral dose was lower by a factor of 3.3 as compared to 
intensity-modulated radiotherapy with photons (IMXT).
Conclusion: IMPT and spot scanning technology allow a potentially clinically useful approach which is also applicable to spare 
other critical structures passing through a target volume, including spinal cord, optic nerves, chiasm, brain stem, or urethra. 
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Ringförmige Hochdosiskonfiguration für die Protonentherapie 
Hintergrund: Die Autoren berichten über Konzeption und erste klinische Anwendung einer ringförmig konfigurierten Dosis für 
die Protonentherapie (PT). Dies erlaubt es, einen möglichst hohen Anteil des Zielvolumens mit der verordneten Dosis zu behan-
deln bei gleichzeitiger Schonung kritischer Strukturen, welche das Zielvolumen durchqueren. 
Methodik und Ergebnisse: Unter Anwendung intensitätsmodulierter Protonentherapie (IMPT) und „Spot-Scanning“-Technologie 
konnte eine Hochdosiskonfiguration in Form eines Donuts generiert und problemlos appliziert werden. Damit konnten > 75% des 
Zielvolumens mit mindestens 95% der verordneten Dosis von 72,8 CGE behandelt werden bei gleichzeitiger Schonung der Cauda 
equina, welche mit lediglich 60–65 CGE belastet wurde. Die Integraldosis im gesunden Gewebe war um den Faktor 3,3 kleiner als 
bei Bestrahlung mit intensitätsmodulierten Photonen (IMXT). 
Schlussfolgerung: IMPT und „Spot-Scanning“-Technologie erlauben einen neuen Ansatz für die optimierte PT, der auch zur 
Schonung anderer kritischer Strukturen eingesetzt werden kann, welche das Zielvolumen durchqueren, wie z.B. Rückenmark, 
Nervus opticus, Chiasma, Hirnstamm oder Urethra. 
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Introduction 
Spot scanning proton therapy (PT) is the result of more than 5 
decades of applied particle physics [6] and radiobiology re-
search [15]. Here, we report on the conception and first clini-
cal application of a novel high-dose configuration in PT, al-
lowing an improved treatment – intensification of dose to the 
target (PTV), for PTVs encompassing a critical (i.e., dose-lim-
iting) structure, like in this case, the cauda equina, whilst at the 
same time delivering minimal dose to the healthy normal 
structures surrounding the PTV, reducing integral dose. This 
goal has been achieved applying intensity modulation meth-
ods for PT (IMPT) using spot scanning [9, 16]. 
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Our patient needed adjuvant PT after macroscopically 
complete resection of a large chordoma of the fifth lumbar 
vertebra (L5). The vertebra had been removed and titanium 
implanted for mechanical stabilization. Chordomas are char-
acterized by high rates of local failure, even if treated with 
60 Gy (photons), or the corresponding equivalence dose 
(60Co Gy equivalents [CGE]) using charged particles [2, 3, 7, 8, 
13, 14, 17, 20, 21]. In PT, the dose is prescribed in CGE, based 
on a conversion by 1.1 of physical proton dose to account for 
enhanced biological effectiveness of protons versus photons 
[15]. However, the cauda region only tolerates a dose of 
60–65 CGE; otherwise, the risk of developing clinically appar-
ent nerve damage is estimated > 10% [1, 4]. 
Our goal hence was to deliver 72 CGE to as much as pos-
sible of the PTV, which included the cauda, whilst restricting 
dose delivered to this critical structure. Conventionally, this 
problem is dealt with in PT by compromising dose to more 
of the PTV, delivering a modified high-dose configuration in 
the second treatment series, treating only the proximal aspect 
of the PTV, which can be reached by protons without pas-
sing through the critical structure within, in this case, the cau-
da. We decided to explore the possibilities of IMPT to gener-
ate a “donut-shaped” high-dose configuration for treatment 
in the second series, allowing an intensification of PTV dose 
coverage. 
Methods 
Intensity modulation methods for PT as well as a first clinical 
example have been published [9, 10]. In brief, in conventional 
spot scanning PT, the dose delivered to each individual point 
(“spot”) in the three-dimensional (3-D) coordinate grid of the 
region of interest is weighted so as to generate a dose distribu-
tion within the PTV, which is as homogeneous as feasible and 
at least 95% of the reference dose. In IMPT, dose within the 
PTV is intentionally inhomogeneous within a given field, as 
defined by the planner. Only the sum of two or three fields 
adds up to the prescribed treatment dose.
In order to apply PT and IMPT, the positioning of the 
patient is important. To this end, we perform CT scout 
view-based controls and correction of patient position before 
every single treatment [11], allowing to place nonmoving re-
gions of interest within 0.5–3 mm as compared to the planning 
setup. In IMPT, if positioning is not precise, the complemen-
tary intensity-modulated (intentionally nonhomogeneous) 
treatment plans would not match as predicted, causing hidden 
hot spots in normal tissue, endangering safety, and cold spots 
within other aspects of the PTV, endangering tumor control.
In this case, the PTV was defined as the preoperative tu-
mor bed and the tissue estimated to have been touched during 
surgery, plus a 5-mm margin in 3-D. CT artifacts from titanium 
implants were compensated manually according to clinician’s 
best judgment and assigning water- and bone-equivalent 
Hounsfield units for dose calculation. The treatment required 
IMPT already in the first series due to the depth range of the 
PTV, which was > 200 mm in water-equivalent density, and a 
limited number of range shifter plates available at the gantry 
(depth range of the Bragg peak with a specific energy of the 
proton beam: 173.5 mm in water-equivalent density). Hence, 
two energies (166 and 177 MeV) were combined to cover the 
depth range homogeneously with dose. To spare the cauda 
(second series), IMPT methods were applied to calculate spot 
weights generating a dose distribution delivering only 65–75% 
of the reference dose to the cauda region. 
Moreover, PT and the choice of beam directions are re-
stricted by respiratory movement, as it would seriously distort 
dose deposition, unless beam directions are quasi parallel to 
the movement. In that case, dose distribution is affected only 
marginally. Safety concerns oblige us to treat the patients with 
the beam coming from above ± 100° due to the geometric con-
struction of our gantry; with beam from below, the patient ta-
ble would rise > 3 m above ground, which could be dangerous 
in the case of panic attacks in patients or an acute medical 
emergency. We hence treat tumors along the spine (between 
C3 and the sacrum) with patients positioned in the prone posi-
tion and use two beam directions, which are ± 10° from poste-
rior (above) for treatment, so-called “narrow-angle” PT and 
IMPT. 
This patient, like all our patients, was treated after giving 
informed written consent. Side effects were scored according 
to common terminology criteria for adverse events (CTCAE, 
http://ctep.cancer.gov/forms/CTCAEv3.pdf). For a compari-
son, an intensity-modulated photon (IMXT) plan (five fields) 
similarly sparing the cauda was prepared.
Results 
The first series to 35 CGE hence did not spare the cauda and 
consisted of four fractions of 2.0 and 15 fractions of 1.8 CGE. 
The dose per fraction was reduced because of several unavoid-
able implant-associated hot spots of up to 124%. In the second 
series, we used identical beam directions and fractionation, 
delivering the donut-shaped high-dose configuration selec-
tively sparing the cauda (Figure 1). In the combined treat-
ment, a total dose of 72.8 CGE was delivered in 40 fractions 
(maximum dose: 88.8 CGE; hot spot within implant material). 
With this approach, it was possible to treat 75.8% of the target 
to at least 95% (69 GCE) of the reference dose. Of the cauda, 
11.4 ml received > 60 CGE; < 1 ml received > 65 CGE (maxi-
mum: 70.5 CGE in a hot spot). Without donut configuration 
generated using IMPT, much less of the target would have re-
ceived 69 CGE, both for technical reasons (target depth range 
> 200 mm in water equivalence) and cauda dose restriction. 
The treatment was tolerated without a problem; only a 
grade 2 skin reaction was noted, yet no other symptom. At the 
proofreading of the manuscript, 28 months after treatment, 
the patient is without late symptoms or radiologic evidence 
for disease. 
IMXT could achieve a similar level of dose sparing to the 
cauda (Figure 2), however, only IMPT can do so whilst simul-
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taneously sparing surrounding structures very effectively. Fig-
ure 3 shows the difference regarding small intestines. The in-
tegral dose to non-target tissue was lower by a factor of 3.3 in 
the case of IMPT versus IMXT.
Discussion
IMPT is suitable to selectively reduce dose delivered to a de-
fined volume within a PTV, hence protecting a critical 
(dose-limiting) structure within the target. This allows an in-
tensification of target dose coverage, and therefore, the prob-
abilistic chances for a cure over a level that would be possible 
using conventional spot-scanning PT. Based on current knowl-
edge, such dose intensification is presumed to be without gen-
erating a higher risk for the development of late normal tissue 
toxicity and organ dysfunction.
Comparative planning revealed only moderate doses to 
the intestines at risk, if IMXT had been used for treatment. 
One can thus say that in this particular case, the expected tox-
icity from delivering the whole treatment with IMXT would 
have been acceptable. This, nevertheless, is an exception, as 
the PTV was situated caudal to the kidneys. In the case of a 
more cranial location of the target (L4 and above), however, 
% 
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CT artifact 
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Figure 1. Proton doses in the middle plane of the target volume (PTV; 
green outline) during the second treatment series. Red lines represent 
anatomic structures and technical volumes. In the first series, the dose 
inside the target was planned to be > 95% using IMPT to allow com-
bining dose delivery by two energies (166 and 177 MeV), to cover the 
entire depth of the PTV (> 200 mm in water-equivalent density); dose 
levels outside the target were identical, however. Artifact correction: 
manual. 
Abbildung 1. Protonendosis in der Mittelschicht des Zielvolumens 
(PTV; grüne Linie) während der zweiten Bestrahlungsserie (siehe Text). 
Rote Linien umranden anatomische Strukturen und technische Volu-
men. In der ersten Serie war die Dosisverteilung außerhalb des PTV 
identisch, innerhalb des PTV jedoch mindestens 95% der verordneten 
Dosis. Dies war nur möglich unter Verwendung der intensitätsmodu-
lierten Protonentherapie (IMPT), sodass die beiden Energien (166 und 
177 MeV) kombiniert zur Anwendung kommen konnten; so konnte die 
gesamte Tiefe des PTV (> 200 mm Wasser-äquivalente Distanz) mit 
Dosis abgedeckt werden. Die Korrektur der Implantat-bedingten Arte-
fakte im CT-Datensatz erfolgte manuell. 
Figure 2. Radiation doses 9 mm cranially to the middle plane of the 
target (PTV; exterior yellow outline) during the second series of the 
treatment. The inner yellow line shows the preoperative tumor vol-
ume and the tissue touched by surgery. Green outlines show cauda as 
well as a technical volume around the cauda (cauda + 5 mm in 3 D), and 
intestines. Note that the color code regarding the dose is different 
from the one used in Figure 1. The upper plan depicts doses generated 
by IMXT (comparative planning), whereas the lower plan depicts the 
doses generated using IMPT (as delivered in the second series). 
Abbildung 2. Dosisverteilung 9 mm kranial der Mittelschicht des Ziel-
volumens (PTV, äußere gelbe Linie) während der zweiten Bestrah-
lungsserie. Die innere gelbe Linie umrandet das Tumorbett sowie das 
Operationsgebiet. Die grünen Linien umringen die Cauda sowie ein 
technisches Volumen darum herum (Cauda + 5 mm in 3-D) und Gedär-
me. Die Farbkodierung der Dosisverteilung ist ebenfalls anders als in 
der Abbildung 1. Oben in der Abbildung findet sich die Dosisverteilung 
bei IMXT, unten jene bei IMPT. 
IMXT
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the limited tolerance of the kidneys and lung [1, 4, 23] would 
have restricted total dose applicable by IMXT alone to 
58–60 CGE, as has already been reported regarding IMXT for 
chordoma of the cervical spine [5], although technically, dose 
to the spinal cord and cauda equina can be restricted to their 
respective tolerance levels. 
On the other hand, IMXT could be tolerated at these 
more proximal sites (L4 and above), if the second series were 
delivered with PT; even conventional photon radiotherapy in 
the first series could be tolerated, if it were followed by IMPT 
in the second (or vice versa). The combination of these tech-
niques could be considered to increase the number of patients 
benefiting from PT in terms of achieving a potentially curative 
target dose. At the Paul Scherrer Institute, patients are treat-
ed with protons alone, unless stipulated otherwise by the an-
nual accelerator shut down for maintenance. In one case, we 
have actually recently treated a patient with chordoma of L2 
with a similar, donut-shaped plan in a first series (IMPT), to 
be followed by conventional radiotherapy (13 × 2 Gy) at the 
referring center. 
Moreover, irradiation of non-target tissues by IMXT is 
clearly an avoidable risk for the induction of treatment-in-
duced secondary cancer [18], and in this particular case, for 
example, the integral dose delivered to the tissues outside the 
PTV would have been much higher (namely, by a factor of 
3.3; see above) by using IMXT instead of IMPT. Previous 
studies have shown similar findings regarding integral dose 
and lifetime risk for secondary cancer; all were much in favor 
of PT and IMPT over XT or IMXT [12, 
19, 22]. These considerations, obviously, 
are particularly significant: when they 
concern the treatment of children and 
young adults, especially as some of them 
may, in fact, be genetically predisposed; 
or regarding the combination of irradia-
tion with chemotherapy. 
The concept we present here is also 
suitable to intensify dose delivered to 
PTVs at other anatomic sites which are 
crossed by other critical anatomic struc-
tures, like, e.g., spinal cord, optic nerves, 
chiasm, brain stem, and esophagus; and 
it is applicable to treatments with other 
positively charged particles, such as car-
bon ions. 
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Figure 3. Comparative dose-volume histogram regarding intestines at risk (Figures 1 and 2). 
Abbildung 3. Vergleichendes Dosis-Volumen-Histogramm betreffend die mitbestrahlten 
Gedärme. 
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